Subscribe to RSS
Download PDF
DOI: 10.1055/s-0045-1810013
Large Flat Bone Metastasis from Gastric Neuroendocrine Neoplasm Mimicking a Primary Bone Malignancy: A Rare and Unusual Presentation
Abstract
The presented case illustrates a rare presentation of a well-differentiated neuroendocrine tumor (NET) in the form of a large, infiltrative soft tissue flat bone mass which was ultimately diagnosed as an unusual skeletal metastasis from a gastric NET. While at initial diagnosis, a differential diagnosis of a primary bone tumor was considered based upon pelvic ultrasound and magnetic resonance imaging, the histopathological analysis confirmed a metastatic well-differentiated grade II NET with a MIB-1 labelling index of 5%. In summary, the case underscores the diagnostic and management challenges posed by NET metastases, particularly the potential for bone metastases to present as atypical, aggressive-appearing lesions. It also emphasizes the crucial role of advanced imaging in guiding accurate diagnosis and therapeutic decision-making.
Keywords
neuroendocrine tumors (NETs) - 18F-AlF-NOTA-octreotide - 18FDG PET/CT - SSTR - bone metastasisPublication History
Article published online:
07 July 2025
© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Scopel M, De Carlo E, Bergamo F. et al. Bone metastases from neuroendocrine tumors: clinical and biological considerations. Endocr Connect 2022; 11 (07) e210568
- 2 Hermans BCM, de Vos-Geelen J, Derks JL. et al. Unique metastatic patterns in neuroendocrine neoplasms of different primary origin. Neuroendocrinology 2021; 111 (11) 1111-1120
- 3 Garcia-Torralba E, Spada F, Lim KHJ. et al. Knowns and unknowns of bone metastases in patients with neuroendocrine neoplasms: a systematic review and meta-analysis. Cancer Treat Rev 2021; 94: 102168
- 4 Kim Y, Ahn B, Choi KD. et al. Gastric neuroendocrine tumors according to the 2019 World Health Organization grading system: a single-center, retrospective study. Gut Liver 2023; 17 (06) 863-873
- 5 Cives M, Strosberg JR. Gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin 2018; 68 (06) 471-487
- 6 Zamborsky R, Svec A, Kokavec M, Galbavy S. Bone metastases in neuroendocrine tumors. Bratisl Lek Listy 2017; 118 (09) 529-534
- 7 Altieri B, Di Dato C, Martini C. et al; NIKE Group. Bone metastases in neuroendocrine neoplasms: from pathogenesis to clinical management. Cancers (Basel) 2019; 11 (09) 1332
- 8 Van Loon K, Zhang L, Keiser J. et al. Bone metastases and skeletal-related events from neuroendocrine tumors. Endocr Connect 2015; 4 (01) 9-17
- 9 Hou J, Long T, He Z. et al. Evaluation of 18F-AlF-NOTA-octreotide for imaging neuroendocrine neoplasms: comparison with 68Ga-DOTATATE PET/CT. EJNMMI Res 2021; 11 (01) 55
- 10 Pauwels E, Cleeren F, Tshibangu T. et al. 18F-AlF-NOTA-octreotide outperforms 68Ga-DOTATATE/NOC PET in neuroendocrine tumor patients: results from a prospective, multicenter study. J Nucl Med 2023; 64 (04) 632-638